Anticoagulant therapies prevent stroke and recurrent venous thromboembolism for more than 6 million Americans living with atrial fibrillation and 900,000 affected by VTE each year, conditions that together account for up to 320,000 annual deaths. In 2023, Medicare Part D spending on anticoagulants exceeded $25.1 billion, making it the second highest drug class by spend. For value-based care organizations operating under shared financial accountability, appropriate indication confirmation, agent selection, dosing, and duration reassessment are essential levers for reducing preventable complications and avoidable utilization.
AAVBC's Anticoagulation Therapy Utilization Management Quick Reference Guide equips clinicians and care teams with a comprehensive, evidence-aligned reference covering indication criteria, contraindications, DOAC and warfarin selection guidance, CHA2DS2-VASc and HAS-BLED risk stratification, renal and weight-based dosing considerations, drug interaction review, and transition of care standards. Grounded in current ACC, AHA, and CHEST guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams deploy anticoagulation where benefit is most clearly established, with the documentation rigor and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of anticoagulation therapy utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
Anticoagulant therapies prevent stroke and recurrent venous thromboembolism for more than 6 million Americans living with atrial fibrillation and 900,000 affected by VTE each year, conditions that together account for up to 320,000 annual deaths. In 2023, Medicare Part D spending on anticoagulants exceeded $25.1 billion, making it the second highest drug class by spend. For value-based care organizations operating under shared financial accountability, appropriate indication confirmation, agent selection, dosing, and duration reassessment are essential levers for reducing preventable complications and avoidable utilization.
AAVBC's Anticoagulation Therapy Utilization Management Quick Reference Guide equips clinicians and care teams with a comprehensive, evidence-aligned reference covering indication criteria, contraindications, DOAC and warfarin selection guidance, CHA2DS2-VASc and HAS-BLED risk stratification, renal and weight-based dosing considerations, drug interaction review, and transition of care standards. Grounded in current ACC, AHA, and CHEST guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams deploy anticoagulation where benefit is most clearly established, with the documentation rigor and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of anticoagulation therapy utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
